Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has issued a supplemental announcement clarifying the independence of four independent non-executive directors, Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li, in line with Hong Kong Listing Rules. Each has confirmed they are independent under the specified criteria, have no financial or other interests in the company or its subsidiaries, and have no connections with core connected persons that might affect their independence.
The company stressed that this clarification does not alter any other details previously disclosed in its appointment announcement or the 2025 annual circular, which remain fully in force. The move reinforces Livzon’s corporate governance and transparency for shareholders, underlining the integrity of its board’s independent oversight and its compliance with Hong Kong’s regulatory standards.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company listed in Hong Kong, engaged in the research, development and manufacture of medicines and related healthcare products. The group operates through multiple subsidiaries and maintains a board structure that includes executive, non-executive, employee representative and independent non-executive directors to meet governance and listing requirements.
Average Trading Volume: 915,075
Technical Sentiment Signal: Hold
Current Market Cap: HK$30.61B
See more insights into 1513 stock on TipRanks’ Stock Analysis page.